(Corrects Merck’s Reuters Instrument Code in paragraph 3)
April 26 (Reuters) – India’s Sun Pharmaceutical Industries will buy Organon & Co in an all‑cash deal, valuing the U.S. drugmaker at about $11.75 billion including debt, the companies said on Sunday.
Under the definitive agreement, Sun Pharma will buy all the outstanding shares of Organon for $14.00 per share in cash, the companies said in a joint statement.
The deal would give Sun Pharma full ownership of Organon, which was spun off from Merck in 2021 that focuses on women’s health, biosimilars and established medicines.
(Reporting by Mihika Sharma in Bengaluru; Editing by Subhranshu Sahu)
Comments